PhaseBio Pharmaceuticals, Inc. (PHASQ)
Market Cap | 49.00 |
Revenue (ttm) | 818,000 |
Net Income (ttm) | 27.84M |
Shares Out | n/a |
EPS (ttm) | 0.59 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 76 |
Open | n/a |
Previous Close | n/a |
Day's Range | n/a |
52-Week Range | n/a |
Beta | 2.08 |
Analysts | n/a |
Price Target | n/a |
Earnings Date | Mar 22, 2023 |
About PHASQ
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure. The company is also developing PB1046, a vasoactive intestinal peptide analogue for the treatment of pulmonary art... [Read more]
Financial Performance
In 2021, PHASQ's revenue was $10,831, a decrease of -96.62% compared to the previous year's $320,000. Losses were -$131,071, -99.87% less than in 2020.
Financial StatementsNews
PhaseBio Plans for Near-Term Sale Using Structured Process Through Chapter 11 of U.S. Bankruptcy Code
MALVERN, Pa.
PhaseBio Pharmaceuticals Reports Second Quarter 2022 Financial Results and Recent Business Highlights
MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)--PhaseBio Pharmaceuticals Reports Second Quarter 2022 Financial Results and Recent Business Highlights
PhaseBio Pharmaceuticals Reports First Quarter 2022 Financial Results and Recent Business Highlights
MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)--PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies...
PhaseBio Announces Successful Pre-BLA Meeting with U.S. FDA for Bentracimab
MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)--PhaseBio Announces Successful Pre-BLA Meeting with U.S. FDA for Bentracimab
PhaseBio Pharmaceuticals to Participate in the 21st Annual Needham Healthcare Conference
MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)--PhaseBio Pharmaceuticals to Participate in the 21st Annual Needham Healthcare Conference
PhaseBio Announces Positive Results from Phase 2b Trial for Bentracimab
MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)--PhaseBio Announces Positive Results from Phase 2b Trial for Bentracimab
PhaseBio Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Recent Business Highlights
MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $PHAS #Bentracimab--PhaseBio Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Recent Business Highlights
PhaseBio Pharmaceuticals Announces Bentracimab Manufacturing Update
MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $PHAS #TakeItToHeart--PhaseBio Pharmaceuticals Announces Bentracimab Manufacturing Update
PhaseBio Pharmaceuticals to Participate in the Cowen 42nd Annual Health Care Conference
MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $PHAS #TakeItToHeart--PhaseBio Pharmaceuticals to Participate in the Cowen 42nd Annual Health Care Conference
PhaseBio Announces Bentracimab Phase 2b Trial Data Accepted for Late Breaking Clinical Research Presentation at the 2022 American College of Cardiology (ACC.22) Annual Scientific Session
MALVERN, PA & SAN DIEGO--(BUSINESS WIRE)---- $PHAS #ACC22--PhaseBio Announces Bentracimab Phase 2b Trial Data Accepted for Late Breaking Clinical Research Presentation at 2022 ACC Annual Scientific Se...
PhaseBio Pulls Plug On Mid-Stage Hypertension Asset
PhaseBio Pharmaceuticals Inc (NASDAQ: PHAS) is voluntarily ending its Phase 2b trial of pemziviptadil (PB1046) in pulmonary arterial hypertension (PAH). The decision follows COVID-19 impacts on manufa...
PhaseBio Provides Pemziviptadil (PB1046) Program Update
MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $PHAS #TakeItToHeart--PhaseBio Provides Pemziviptadil (PB1046) Program Update
PhaseBio Announces Publication of Interim Results from Pivotal REVERSE-IT Phase 3 Trial of Bentracimab in NEJM Evidence
MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $PHAS #NEJM--PhaseBio Announces Publication of Interim Results from Pivotal REVERSE-IT Phase 3 Trial of Bentracimab in NEJM Evidence
PhaseBio Names Jonathan Birchall as Chief Commercial Officer
MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $PHAS #TakeItToHeart--PhaseBio Names Jonathan Birchall as Chief Commercial Officer
PhaseBio's Shares Slide As Antiplatelet Candidate Shows Higher Rates Of Side Effect
PhaseBio Pharmaceuticals Inc (NASDAQ: PHAS) has announced interim results from the REVERSE-IT Phase 3 trial of bentracimab to reverse the antiplatelet effects of ticagrelor. The trial included patient...
PhaseBio Announces Interim Results from Pivotal REVERSE-IT Phase 3 Trial of Bentracimab for the Reversal of Antiplatelet Effects of Ticagrelor in Patients Requiring Urgent Surgery or Experiencing Uncontrolled Major or Life-Threatening Bleeding
MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $PHAS #TakeItToHeart--PhaseBio Announces Interim Results from Pivotal REVERSE-IT Phase 3 Trial of Bentracimab for the Reversal of Antiplatelet Effects of ...
PhaseBio Reports Third-Quarter 2021 Financial Results and Recent Business Highlights
MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $PHAS #TakeItToHeart--PhaseBio Reports Third-Quarter 2021 Financial Results and Recent Business Highlights
PhaseBio Pharmaceuticals to Host Investor Call to Discuss Interim Results from Pivotal REVERSE-IT Phase 3 Trial Presented at the American Heart Association Annual Meeting
MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $PHAS #AHA2021--PhaseBio Pharmaceuticals to Host Investor Call to Discuss Interim Results from Pivotal REVERSE-IT Phase 3 Trial Presented at AHA Annual Me...
PhaseBio's Bentracimab Reverses Ticagrelor-Associated Antiplatelet Activity In Mid-Stage Study
PhaseBio Pharmaceuticals Inc (NASDAQ: PHAS) has announced topline data from its Phase 2b trial of bentracimab in healthy, older volunteers 50-80 years old. The trial in 150 subjects receiving bentraci...
PhaseBio Announces Topline Results From Phase 2b Trial for Bentracimab
MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $PHAS #TakeItToHeart--PhaseBio Announces Topline Results from Phase 2b Trial for Bentracimab
PhaseBio Announces Interim Analysis of REVERSE-IT Phase 3 Trial Accepted for Late Breaking Science Presentation at the American Heart Association Scientific Sessions 2021
MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $PHAS #AHA21--PhaseBio Announces Interim Analysis of REVERSE-IT Phase 3 Trial at Late Breaker at the American Heart Association Scientific Sessions 2021
PhaseBio Appoints William D. Humphries to Board of Directors
MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $PHAS #TakeItToHeart--PhaseBio Appoints William D. Humphries to Board of Directors
PhaseBio Pharmaceuticals to Present at 23rd Annual H.C. Wainwright Global Investment Conference
MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $PHAS #TakeItToHeart--PhaseBio Pharmaceuticals to Present at 23rd Annual H.C Wainwright Global Investment Conference
PhaseBio Reports Second-Quarter 2021 Financial Results and Recent Business Highlights
MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $PHAS #TakeItToHeart--PhaseBio Reports Second-Quarter 2021 Financial Results and Recent Business Highlights
PhaseBio Pharmaceuticals Achieves Enrollment Milestones Supporting Interim Analysis of REVERSE-IT Global Phase 3 Trial, Enabling Preparation of a BLA submission for Bentracimab for Reversal of Antiplatelet Effects of Ticagrelor
MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $PHAS #TakeItToHeart--PhaseBio Pharmaceuticals Achieves Enrollment Milestones Supporting Interim Analysis of REVERSE-IT Global Phase 3 Trial